Why not resveratrol?

A reader asked me why resveratrol is not in our book The Immortality Edge. Given the hype, fair question. The answer is sitting right there in the question. Hype.

I have watched resveratrol move through the same cycle three or four supplements have moved through in my career. Promising early lab work, an evocative origin story, a wave of internet enthusiasm, hundreds of millions of dollars of investment, and then a long slow unwinding of the original premise. Here is the actual state of play, as cleanly as I can describe it.

The Glaxo Smith Kline story

Resveratrol’s modern hype cycle started with the idea that it activated sirtuins, a class of histone deacetylase enzymes that were thought to be longevity molecules. The leading academic figure in the area, David Sinclair at Harvard, co founded a company called Sirtris Pharmaceuticals to develop sirtuin activating compounds, including more potent synthetic analogs of resveratrol. Glaxo Smith Kline acquired Sirtris in 2008 for roughly $720 million. That number is what put resveratrol on the front page of the wellness internet.

What happened next is less famous. Reports from inside the post acquisition program indicated that the early laboratory data could not be reliably reproduced by GSK’s scientists. The lead clinical candidate, a resveratrol derived compound, was associated with cases of kidney failure in trial subjects. GSK eventually wound down the Sirtris program. Resveratrol as a drug candidate was dead by the early 2010s. That part is documented.

The sirtuin mechanism unraveled

Then the underlying mechanism started to crack. Subsequent work suggested resveratrol probably does not directly activate sirtuins at all, but works through a different class of metabolic energy sensors, the adipokines. That makes resveratrol a metabolic shepherd rather than a longevity molecule, which is not nothing, but is a different story than the one that drove the hype.

The sirtuin story itself also took hits. The longevity gains attributed to sirtuin activation appeared mostly in metabolically stressed animals, not healthy ones. People who naturally express dramatically higher levels of sirtuins, due to a genetic variant, do not live longer than the average population. They also do not live shorter. Sirtuins seem to do useful work when an organism is under metabolic stress, which is real, but they are not the master longevity switch the early framing suggested.

None of this means sirtuins are useless. Aging, diabetes, and obesity are all forms of metabolic stress, so sirtuin activation may yet land as a useful target. Big Pharma will produce a sirtuin activator one of these days. It just will not be resveratrol.

The telomerase claim, tested

Resveratrol has been promoted as both a telomerase activator and a telomerase inhibitor, depending on which marketing copy you read. There are scenarios where a compound can act both ways depending on cell type, so the contradiction is not automatically disqualifying. I wanted to know what the actual answer was, so I worked with Dr. Bill Andrews, who has run telomerase activity assays on more compounds than almost anyone, and we tested several commercial resveratrol samples from reputable manufacturers.

None of them showed meaningful telomerase activation in our tests. Not one. Other people have run similar work and reported similar results. Whatever resveratrol does, activating telomerase is not on the list.

One footnote. There is a longevity adjacent personality who runs a forum, has been popular for years, and at one point was selling his own resveratrol brand alongside other supposed telomerase activators. His resveratrol formulation was toxic to human cells at relatively low concentrations in our testing, and his telomerase activators did not activate telomerase. He has since added TA-65 to his store, which actually does activate telomerase, so he eventually got something right.

So is resveratrol worthless?

Generally no, if you get a clean source. As a plant derived polyphenol, resveratrol is a competent antioxidant, and through its adipokine activity it has shown signal in metabolic health, particularly in people with insulin resistance or type 2 diabetes. It is not poisonous, it is not a scam, and it may modestly help in specific metabolic contexts.

What it is not is a telomerase activator, a sirtuin master switch, or a longevity drug. The data simply do not support those framings.

The compound we chose instead

In The Immortality Edge we chose to highlight the polyphenolic extract of aronia melanocarpa, the chokeberry, which has the highest polyphenol density, anthocyanin content, and flavonol content of all the berry families, including blueberries. Aronia is not a telomerase activator either. It is a potent broad spectrum antioxidant with metabolic effects, and in head to head antioxidant capacity testing it outperforms resveratrol on most measures. When aronia gets the same level of investment resveratrol has gotten, my guess is it will hold up better.

What this means for you

• If you like resveratrol and have been taking it for a while, you can keep taking it. It is not harmful, and it has reasonable metabolic and antioxidant support.
• Do not expect it to function like a telomerase activator. It does not.
• If you want telomerase support, the only compound with human safety and human efficacy data is TA-65, which is what the actual clinical literature points at.
• The general lesson, which I will keep repeating, is that the size of the marketing campaign is not the same as the size of the evidence. Sometimes the gap is small. Sometimes the gap is enormous.

— Doc